#Flash: Letrozole is Effective in the treatment of postmenop
Researchers aimed to compare the extended therapy with letrozole for 5 years versus the standard duration of 2–3 years of letrozole in postmenopausal patients with breast cancer who have already received 2–3 years of tamoxifen. 2056 patients were enrolled and randomly assigned to receive letrozole for 2–3 years. In postmenopausal patients with breast cancer, extended treatment with letrozole resulted in a significant improvement in disease-free survival compared with the standard 2–3 years of letrozole. Sequential endocrine therapy with tamoxifen for 2–3 years followed by letrozole for 5 years should be considered as one of the optimal standard endocrine treatments for postmenopausal patients with hormone receptor-positive breast cancer.

If you find this post insightful, please like, comment and share.

Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00352-1/fulltext
Like
Comment
Share